Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

57
Biotech: Take It On The Run

2018-07-05 seekingalpha - 7
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making.
BLCM SLDB GLMD LOXO INCY ARQL NTEC KDMN SRPT MGTX AQXP 4508 IFRX MTZXF ARGX GWPH MTZPY NVS CTMX GWP

179
Here Are 43 Of 84 'Safer' Healthcare High Yield Dividend Equities For June

2018-06-27 seekingalpha
AbbVie took net gain "safer" June high yield dividend Healthcare honors. Its projected 22.9% net gain is better than Gilead's and way ahead of Novartis's result, per analyst targets of 6/22/18.
ABT GRFS GILD ABT 4508 SNY MDT RHHBF MTZXF NVSEF RHHVF MTZPY NVO JNJ RHHBY NVS ABBV PFE ABBV

2
With a Strong Focus on ALS Patients, Mitsubishi Tanabe Pharma America Works to Increase Access an...

2018-06-01 biospace
It has been one year since Mitsubishi Tanabe Pharma America’s (MTPA) Radicava was approved as the first treatment for amyotrophic lateral sclerosis (ALS) in more than 20 years. Since its approval, MTPA has been aggressive in its efforts to get the medication in the hands of ALS patients. The drug officially rolled out to U.S. patients in August 2017.
MTZXF MTZPY 4508

2
Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2018 Results - Earnings Call Transcript

2018-05-14 seekingalpha
Good afternoon, ladies and gentlemen, and thank you for holding. Welcome to Dyadic International's First Quarter 2018 Financial Results Conference Call. Now, all participants are in a listen-only mode. My name is Dana and I'll be your conference coordinator today. As a reminder, please note that this call is being recorded.
MTZXF MTZPY DYAI 4508

15
Regeneron Pharmaceuticals (REGN) Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha - 1
Welcome to the Regeneron Pharmaceuticals First Quarter 2018 Earnings Conference Call. My name is Jason and I will be your operator. At this time all participants will be in a listen-only mode. Later, we will have a question-and-answer session. Also, please note this conference is being recorded.
MTZXF REGN MTZPY GCVRZ SAN SNYNF 4508 SNY

2
The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®

2018-04-27 globenewswire
Valby, Denmark, 27 April 2018 - H. Lundbeck A/S (Lundbeck) today announced that Lexapro® (escitalopram oxalate), which is distributed by Mochida Pharmaceutical Co., Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) in Japan, is expected to receive a final confirmation of the extension of the eight-year market exclusivity by the Japanese Ministry of Health, Labour and Welfare (MHLW).
MTZXF MTZPY 4508

2
Det japanske Sundheds-, arbejds- og socialministerium (MHLW) accepterer en forlængelse af markedseksklusivitet på to år for Lexapro®

2018-04-27 globenewswire
Valby, Danmark, 27. april 2018 - H. Lundbeck A/S (Lundbeck) annoncerede i dag, at Lexapro® (escitalopram oxalat), som markedsføres af Mochida Pharmaceutical Co., Ltd. (Mochida) og Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) i Japan, forventes at modtage endelig bekræftelse på en forlængelse af den otteårige markedseksklusivitet af det japanske Sundheds-, arbejds- og socialministerium (Ministry of Health, Labour and Welfare – herefter MHLW).
MTZXF MTZPY 4508

2
Neuraltus Weighs Future of Lead Candidate NP001 After Failure in Phase II ALS Trial

2018-04-26 genengnews
Neuraltus Pharmaceuticals said today it is weighing if, and how, it plans to continue developing its lead candidate NP001 after it failed a Phase II confirmatory study in ALS patients with elevated levels of systemic inflammation—a review that makes the drug unlikely to be the third approved treatment for the disease any time soon, if ever.
MTZXF MTZPY 4508

2
Amgen Backs Launch of Golden Ticket Winning ALS Company QurAlis

2018-04-05 biospace
After winning Amgen’s coveted 2017 Golden Ticket in December 2017 startup company QurAlis officially launched with financial backing from Amgen Ventures with a mission to develop a cure for Amyotrophic Lateral Sclerosis (ALS).
MTZXF MTZPY 4508

2
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2017 Results - Earnings Call Transcript

2018-03-28 seekingalpha
Good afternoon, ladies and gentlemen. Thank you for holding. Welcome to Dyadic International’s 2017 Year-End Financial Results Conference Call. At this time all participants are in a listen-only mode. My name is Catherine, I will be your conference coordinator for today. As a reminder, please note that this call is being recorded.
MTZXF MTZPY DYAI 4508

2
Dyadic International Announces 2017 Year End Results and Recent Developments

2018-03-27 globenewswire
JUPITER, Fla., March 27, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying our proprietary C1 gene expression platform to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2017, and recent company developments.
MTZXF MTZPY DYAI 4508

14
Akebia Announces $85M Public Offering

2018-03-23 biospace
Cambridge, Massachusetts-based Akebia Therapeutics announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.
MTZXF MTZPY MS 4508

11
VIVUS Reports Fourth Quarter 2017 Financial Results

2018-03-13 marketwired
CAMPBELL, CA--(Marketwired - March 13, 2018) - VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter and year ended December 31, 2017 and provided a business update.
VVUS MTZXF MTZPY 4508

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 606813202